Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41–BEVANEC randomized phase II study

Patients with gastroenteropancreatic (GEP), metastatic or locally advanced, non-resectable, grade 3 poorly-differentiated neuroendocrine carcinoma (NEC) are treated with cisplatin (or carboplatin)-etoposide in first-line palliative chemotherapy (CT1). However, nearly all patients will develop resist...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Digestive and liver disease 2018-02, Vol.50 (2), p.195-198
Hauptverfasser:	Walter, Thomas, Malka, David, Hentic, Olivia, Lombard-Bohas, Catherine, Le Malicot, Karine, Smith, Denis, Ferru, Aurélie, Assenat, Eric, Cadiot, Guillaume, Lievre, Astrid, Kurtz, Jean-Emmanuel, Dahan, Laetitia, Dubreuil, Olivier, Hautefeuille, Vincent, Lepere, Céline, Gangloff, Alice, Elhajbi, Farid, Coriat, Romain, Roquin, Guillaume, Bouarioua, Nadia, Granger, Victoire, Scoazec, Jean-Yves, Lepage, Côme
Format:	Artikel
Sprache:	eng
Schlagworte:	Bevacizumab Cancer Clinical trial FOLFIRI Gastroenteropancreatic Life Sciences Neuroendocrine carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!